Literature DB >> 9570691

Comparative nephrotoxicity of some antitumour-active platinum and ruthenium complexes in rats.

L Kersten1, H Bräunlich, B K Keppler, C Gliesing, M Wendelin, J Westphal.   

Abstract

The nephrotoxicity of three platinum (CPL, KP734, KP735) and three ruthenium coordination complexes (KP418, KP692, KP1019) was tested in rats in comparison to cisplatin (CP). Renal functional changes (excretion of water, protein, p-aminohippurate (PAH) and osmolytes) were not observed after the administration of 10% of the LD450 of the compounds given twice a week for up to 5 weeks. After a relatively high single dose of the substances (50% of the LD50), signs of nephrotoxicity on the day of maximal renal damage decreased in the following order: CP, KP418, CPL, KP734, KP735, KP692 and KP1019. In comparison to CP, proteinuria was significantly lower after the administration of any of the compounds, especially KP692 and KP1019. Neither renal lipid peroxidation (TBARS) nor glutathion status (GSH, GSSG) was affected. In summary, KP735 in the group of platinum complexes and KP1019 in the ruthenium group had the lowest nephrotoxicity. Other investigators have shown that all complexes induced anti-neoplastic activity under analogous experimental conditions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9570691     DOI: 10.1002/(sici)1099-1263(199803/04)18:2<93::aid-jat472>3.0.co;2-w

Source DB:  PubMed          Journal:  J Appl Toxicol        ISSN: 0260-437X            Impact factor:   3.446


  6 in total

1.  Modulation of activity of known cytotoxic ruthenium(III) compound (KP418) with hampered transmembrane transport in electrochemotherapy in vitro and in vivo.

Authors:  Rosana Hudej; Damijan Miklavcic; Maja Cemazar; Vesna Todorovic; Gregor Sersa; Alberta Bergamo; Gianni Sava; Anze Martincic; Janez Scancar; Bernhard K Keppler; Iztok Turel
Journal:  J Membr Biol       Date:  2014-06-24       Impact factor: 1.843

2.  Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR.

Authors:  Naniye Cetinbas; Michael I Webb; Joshua A Dubland; Charles J Walsby
Journal:  J Biol Inorg Chem       Date:  2009-08-26       Impact factor: 3.358

3.  Experimental study on effects of deferoxamine mesilate in ameliorating cisplatin-induced nephrotoxicity.

Authors:  E Ozdemir; A I Dokucu; A K Uzunlar; A Ece; M Yaldiz; H Oztürk
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

4.  Growth inhibitory effects of the Diruthenium-Ibuprofen compound, [Ru2Cl(Ibp) 4], in human glioma cells in vitro and in the rat C6 orthotopic glioma in vivo.

Authors:  Marcel Benadiba; Iguatinã de M Costa; Rodrigo L S R Santos; Fernanda Oliveira Serachi; Denise de Oliveira Silva; Alison Colquhoun
Journal:  J Biol Inorg Chem       Date:  2014-05-14       Impact factor: 3.358

5.  Dose-dependent protection on cisplatin-induced ototoxicity - an electrophysiological study on the effect of three antioxidants in the Sprague-Dawley rat animal model.

Authors:  Guiscardo Lorito; Stavros Hatzopoulos; Göran Laurell; Kathleen C M Campbell; Joseph Petruccelli; Pietro Giordano; Krzysztof Kochanek; Lech Sliwa; Alessandro Martini; Henryk Skarzynski
Journal:  Med Sci Monit       Date:  2011-08

6.  Lipid peroxides and antioxidant enzymes in cisplatin-induced chronic nephrotoxicity in rats.

Authors:  Ricardo González; Cheyla Romay; Aluet Borrego; Frank Hernández; Nelson Merino; Zullyt Zamora; Enis Rojas
Journal:  Mediators Inflamm       Date:  2005-08-14       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.